首页> 外文期刊>Bone marrow transplantation >Insulin-like growth factor-I predicts sinusoidal obstruction syndrome following pediatric hematopoietic stem cell transplantation.
【24h】

Insulin-like growth factor-I predicts sinusoidal obstruction syndrome following pediatric hematopoietic stem cell transplantation.

机译:胰岛素样生长因子-1预测小儿造血干细胞移植后的正弦梗阻综合征。

获取原文
获取原文并翻译 | 示例
       

摘要

Sinusoidal obstruction syndrome (SOS) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT) initiated through damage of sinusoidal endothelium and inflammation. Insulin-like growth factor-l (IGF-l) maintains and repairs endothelium and intestinal mucosa. We hypothesized that low IGF-l levels may increase the risk of inflammatory complications, such as SOS, in HSCT-patients. We prospectively measured IGF-l concentrations in 121 pediatric patients before, during, and after allogeneic HSCT. Overall, IGF-l levels were significantly reduced compared with healthy sex- and age-matched children. IGF-I levels pre-HSCT and at day 0 were inversely associated with C-reactive protein levels, hyperbilirubinemia, and number of platelet transfusions within the first 21 days post-transplant. Low levels of IGF-I before conditioning and at day of transplant were associated with increased risk of SOS diagnosed by the modified Seattle criteria (pre-HSCT: OR?=?1.7 (95% CI: 1.2-2.6, p?=?0.01), and the pediatric EBMT criteria (pre-HSCT: 1.7 (1.2-2.5, p?=?0.009) and day 0: 1.7 (1.3-2.5, p?=?0.001)/SDS decrease in IGF-1). These data suggest that IGF-I is protective against cytotoxic damage and SOS, most likely through trophic effects on endothelial cells and anti-inflammatory properties, and may prove useful as a predictive biomarker of SOS.
机译:正弦梗阻综合征(SOS)是通过损伤正弦内皮和炎症的造血干细胞移植(HSCT)的潜在致命并发症。胰岛素样生长因子-1(IGF-1)维持和修理内皮和肠粘膜。我们假设低IGF-L水平可能会增加HSCT患者中炎症并发症的风险,例如SOS。在同种异体的HSCT之前,期间和之后,我们前瞻性地测量了121名儿科患者的IGF-L浓度。总体而言,与健康的性行为和年龄匹配的儿童相比,IGF-L水平显着减少。 IGF-I水平预先HSCT和第0天与移植后前21天内的C反应蛋白水平,高胆血症血症和血小板输注数与逆转。在调理之前和移植日之前的IGF-I水平与由改进的西雅图标准诊断的SOS的风险增加有关(PRE-HSCT:或?=?1.7(95%CI:1.2.2.6,P?= 0.01 )和儿科ebmt标准(Pre-HSCT:1.7(1.2-2.5,P?= 0.009)和第0天:1.7(1.3-2.5,P?0.001)/ SDS在IGF-1中减少)。这些数据表明IGF-I对细胞毒性损伤和SOS保护,最有可能通过对内皮细胞和抗炎特性的营养效果,并且可以作为SOS的预测生物标志物。

著录项

  • 来源
    《Bone marrow transplantation》 |2021年第5期|共10页
  • 作者单位

    Department of Pediatrics and Adolescent Medicine Rigshospitalet University of Copenhagen;

    Department of Pediatrics and Adolescent Medicine Rigshospitalet University of Copenhagen;

    Department of Pediatrics and Adolescent Medicine Rigshospitalet University of Copenhagen;

    Department of Pediatrics and Adolescent Medicine Rigshospitalet University of Copenhagen;

    Department of Growth and Reproduction Rigshospitalet University of Copenhagen;

    Department of Pediatrics and Adolescent Medicine Rigshospitalet University of Copenhagen;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号